The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer

Thomas, JS, Hanby, AM orcid.org/0000-0001-7966-1570, Russell, N et al. (10 more authors) (2017) The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer. Breast Cancer Research and Treatment, 163 (1). pp. 63-69. ISSN 0167-6806

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Keywords: Breast cancer; Radiation therapy; Clinical trial; Pathology; Quality assurance
Dates:
  • Published: 1 May 2017
  • Accepted: 6 February 2017
  • Published (online): 11 February 2017
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Pathology & Tumour Biology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 03 Mar 2017 11:24
Last Modified: 05 Oct 2017 16:27
Status: Published
Publisher: Springer Verlag
Identification Number: https://doi.org/10.1007/s10549-017-4145-4

Share / Export

Statistics